HRP20171937T1 - Pripravci za i postupci ispitivanja toksigenosti - Google Patents
Pripravci za i postupci ispitivanja toksigenosti Download PDFInfo
- Publication number
- HRP20171937T1 HRP20171937T1 HRP20171937TT HRP20171937T HRP20171937T1 HR P20171937 T1 HRP20171937 T1 HR P20171937T1 HR P20171937T T HRP20171937T T HR P20171937TT HR P20171937 T HRP20171937 T HR P20171937T HR P20171937 T1 HRP20171937 T1 HR P20171937T1
- Authority
- HR
- Croatia
- Prior art keywords
- bont
- hips
- evaluating
- biologically active
- activity
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (15)
1. Postupak procjene neurotoksina iz bakterije Clostridium botulinum (BoNT) na aktivnost, naznačen time što se sastoji u:
a) stavljanju u kontakt živčane stanice nastale iz ljudske inducirane pluripotentne matične stanice (hiPS) s pripravkom koji sadrži BoNT; i
b) procjeni navedenog BoNT na biološku aktivnost.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što dodatno uključuje korak stavljanja u kontakt navedenog BoNT s ispitivanim spojem prije stavljanja u kontakt navedenih živčanih stanica nastalih iz hiPS.
3. Postupak u skladu s patentnim zahtjevom 2, naznačen time što je navedeni ispitivani spoj protutijelo.
4. Postupak u skladu s patentnim zahtjevom 3, naznačen time što je navedeno protutijelo neutralizirajuće protutijelo.
5. Postupak u skladu s patentnim zahtjevom 4, naznačen time što je navedeno neutralizirajuće protutijelo prisutno u uzorku koji se bira iz skupine koju čine pročišćena protutijela, serum i antitoksini.
6. Postupak procjene neurotoksina iz bakterije Clostridium botulinum (BoNT) na aktivnost, naznačen time što se sastoji u:
a) stavljanju u kontakt živčane stanice nastale iz ljudske inducirane pluripotentne matične (hiPS) stanice s pripravkom koji sadrži i) BoNT; i ii) neutralizirajuće protutijelo; i
b) procjeni navedenog BoNT na biološku aktivnost.
7. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što navedeni BoNT ima serotip koji se bira iz skupine koju čine A, B, C, E i modificirane varijante navedenih BoNT.
8. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što se navedenu biološku aktivnost bira iz skupine koju čine cijepanje SNAP-25, cijepanje VAMP2 i otpuštanje neurotransmitera.
9. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je navedeno ispitivanje kvalitativno.
10. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je navedeno ispitivanje kvantitativno.
11. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što je navedeni BoNT pročišćen.
12. Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što je navedeni BoNT u kompleksu.
13. Postupak u skladu s bilo kojim od patentnih zahtjeva 6 do 12, naznačen time što je navedeno neutralizirajuće protutijelo prisutno u uzorku koji se bira iz skupine koju čine pročišćena protutijela, serum i antitoksini.
14. Postupak određivanja količine biološki aktivnog BoNT u pripravku koji sadrži biološki aktivni BoNT, naznačen time što se navedeni postupak sastoji u koracima:
(a) stavljanja u kontakt živčane stanice nastale iz stanice hiPS s uzorkom pripravka koji sadrži biološki aktivni BoNT; i
(b) određivanja količine biološki aktivnog BoNT prisutnog u pripravku procjenom navedenog uzorka na biološku aktivnost BoNT.
15. Upotreba živčane stanice nastale iz ljudske inducirane pluripotentne matične (hiPS) stanice, naznačena time što je navedena živčana stanica namijenjena procjeni BoNT na aktivnost.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161540693P | 2011-09-29 | 2011-09-29 | |
| PCT/US2012/057825 WO2013049508A1 (en) | 2011-09-29 | 2012-09-28 | Compositions and methods for toxigenicity testing |
| EP12835606.0A EP2761065B1 (en) | 2011-09-29 | 2012-09-28 | Compositions and methods for toxigenicity testing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171937T1 true HRP20171937T1 (hr) | 2018-02-09 |
Family
ID=47996425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171937TT HRP20171937T1 (hr) | 2011-09-29 | 2012-09-28 | Pripravci za i postupci ispitivanja toksigenosti |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9217172B2 (hr) |
| EP (1) | EP2761065B1 (hr) |
| JP (1) | JP5877617B2 (hr) |
| KR (1) | KR101640694B1 (hr) |
| CN (1) | CN103958747B (hr) |
| AU (1) | AU2012315783B2 (hr) |
| BR (1) | BR112014007717B1 (hr) |
| CA (1) | CA2850531C (hr) |
| ES (1) | ES2653249T3 (hr) |
| HR (1) | HRP20171937T1 (hr) |
| HU (1) | HUE037509T2 (hr) |
| IL (1) | IL231768B (hr) |
| LT (1) | LT2761065T (hr) |
| MX (1) | MX348188B (hr) |
| PL (1) | PL2761065T3 (hr) |
| RU (1) | RU2616281C2 (hr) |
| SG (1) | SG11201401007SA (hr) |
| SI (1) | SI2761065T1 (hr) |
| WO (1) | WO2013049508A1 (hr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014301116B2 (en) | 2013-06-28 | 2019-11-14 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells |
| LT3030905T (lt) | 2013-08-09 | 2018-01-25 | Biomadison, Inc. | Padidinto jautrumo botulino toksino tyrimas |
| ES2642916T3 (es) | 2014-06-06 | 2017-11-20 | Galit KLEINER-FISMAN | Toxina botulínica para su uso en el tratamiento de la paratonia |
| EP3590500B1 (en) | 2014-12-23 | 2025-06-25 | Merz Pharma GmbH & Co. KGaA | Botulinum toxin prefilled container |
| WO2017063743A1 (en) | 2015-10-14 | 2017-04-20 | Merz Pharma Gmbh & Co. Kgaa | Improvements to ultrasound-based therapy of photoaged tissue |
| CN108463242A (zh) | 2016-03-02 | 2018-08-28 | 梅尔兹制药公司 | 包含肉毒杆菌毒素的组合物 |
| PL3463432T3 (pl) | 2016-05-27 | 2021-04-19 | Ipsen Biopharm Limited | Ciekła formulacja neurotoksyny stabilizowana tryptofanem lub tyrozyną |
| TWI737742B (zh) | 2016-06-22 | 2021-09-01 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用 |
| EP3290437A1 (en) | 2016-08-31 | 2018-03-07 | Merz Pharma GmbH & Co. KGaA | Novel recombinant clostridial neurotoxins with decreased duration of effect |
| EP3312290A1 (en) * | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| EP3312193A1 (en) | 2016-10-19 | 2018-04-25 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with accelerated onset of effect |
| US10751394B2 (en) * | 2016-10-25 | 2020-08-25 | Cellsnap Llc | Neurotoxins and uses thereof |
| EP3333179A1 (en) | 2016-12-07 | 2018-06-13 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with accelarated onset of effect |
| EP3335719A1 (en) | 2016-12-14 | 2018-06-20 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with a stabilized light chain |
| AU2018237799B2 (en) | 2017-03-24 | 2024-11-14 | Merz Pharma Gmbh & Co. Kgaa | Improved use of botulinum neurotoxin in the treatment of sialorrhea |
| WO2018233813A1 (en) | 2017-06-20 | 2018-12-27 | Merz Pharma Gmbh & Co. Kgaa | NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION |
| EP3649143B1 (en) | 2017-07-06 | 2022-08-31 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
| US20210008156A1 (en) | 2017-10-26 | 2021-01-14 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum neurotoxins with increased duration of effect |
| US20200354706A1 (en) | 2017-11-22 | 2020-11-12 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
| CA3111674A1 (en) * | 2018-09-28 | 2020-04-02 | Ipsen Biopharm Limited | Cell-based clostridal neurotoxin assays |
| EP3860640A1 (en) | 2018-10-02 | 2021-08-11 | Merz Pharma GmbH & Co. KGaA | Novel uses of botulinum neurotoxin for treating lipoedema |
| US12171717B2 (en) | 2018-10-08 | 2024-12-24 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxin prefilled vial |
| KR20210130711A (ko) | 2019-02-21 | 2021-11-01 | 메르츠 파마 게엠베하 운트 코. 카가아 | 진전의 치료를 위한 보툴리눔 신경독의 신규 용도 |
| KR102297991B1 (ko) * | 2019-10-11 | 2021-09-07 | 주식회사 하울바이오 | SNARE 복합체를 억제하는 항-Syntaxin 1A 항체 및 이의 용도 |
| BR112022023413A2 (pt) | 2020-06-05 | 2022-12-20 | Merz Pharma Gmbh & Co Kgaa | Tratamento de rugas faciais com toxina botulínica de alta dose e baixo volume |
| US20220010355A1 (en) * | 2020-07-10 | 2022-01-13 | Galderma Holding SA | Cell based method for determination of botulinum toxin potency based on western blotting |
| CN113774023B (zh) * | 2021-09-28 | 2022-11-25 | 中国食品药品检定研究院 | 人诱导多能干细胞诱导分化神经细胞评价模型的构建及其评价药物神经毒性的用途 |
| WO2023135428A1 (en) | 2022-01-14 | 2023-07-20 | Galderma Holding SA | Treatment of moderate to very severe glabellar lines and lateral canthal lines |
| EP4479012A1 (en) | 2022-02-15 | 2024-12-25 | Merz Pharma GmbH & Co. KGaA | Liquid botulinum toxin formulation and use thereof |
| IL315004A (en) | 2022-02-15 | 2024-10-01 | Merz Pharma Gmbh & Co Kgaa | : Liquid botulinum toxin formulation and its uses |
| TW202400122A (zh) | 2022-02-28 | 2024-01-01 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素用於降低皮膚毛孔尺寸及／或皮脂產生之用途、以及降低皮膚毛孔尺寸及／或皮脂產生的方法 |
| AR131172A1 (es) | 2022-11-28 | 2025-02-19 | Merz Pharma Gmbh & Co Kgaa | Inyección de toxina botulínica en el platisma para el rejuvenecimiento del rostro inferior y del cuello |
| IL320937A (en) | 2022-11-28 | 2025-07-01 | Merz Pharma Gmbh & Co Kgaa | High-concentration botulinum toxin treatment for neck rejuvenation |
| JP2025541064A (ja) | 2022-12-15 | 2025-12-18 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン | ボツリヌス毒素を含む注射可能なゲルおよびその使用 |
| EP4680382A1 (en) | 2023-03-15 | 2026-01-21 | Merz Pharma GmbH & Co. KGaA | A rocking shaker for treating at least one fluid sample |
| WO2024194181A1 (en) | 2023-03-20 | 2024-09-26 | Merz Therapeutics GmbH | Nh3 scavenger for use in the treatment of mobility disability in a post-stroke patient |
| WO2024240868A1 (en) | 2023-05-23 | 2024-11-28 | Merz Therapeutics GmbH | Botulinum toxin for treating peripheral neuropathic pain |
| CN121511091A (zh) | 2023-07-12 | 2026-02-10 | 莫茨药物股份两合公司 | 通过肉毒杆菌毒素的色素沉着过度病况治疗 |
| IL326140A (en) | 2023-08-10 | 2026-03-01 | Merz Pharma Gmbh & Co Kgaa | Liquid formulation of botulinum toxin and its use |
| CN117887797B (zh) * | 2023-12-27 | 2024-09-20 | 中国食品药品检定研究院 | 一种梭状芽胞杆菌神经毒素效价检测方法 |
| WO2025228877A1 (en) | 2024-04-29 | 2025-11-06 | Merz Therapeutics GmbH | Botulinum toxin for the preventive treatment of migraine |
| WO2026021713A1 (en) | 2024-07-23 | 2026-01-29 | Merz Therapeutics GmbH | Uses of magnetic nerve stimulation associated with botulinum neurotoxin administration |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9411138D0 (en) * | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| EP1595951A1 (en) * | 1997-07-21 | 2005-11-16 | Arpi Matossian-Rogers | Diagnosis and treatment of diseases using peptides which are bound by specific anti-anti-t-cell receptor vbeta antibodies |
| US7115399B2 (en) | 2001-07-31 | 2006-10-03 | Allergan, Inc. | Pinna reflex assay |
| US6984375B2 (en) | 2001-08-03 | 2006-01-10 | Allergan, Inc. | Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles |
| US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
| GB2398636A (en) | 2003-02-21 | 2004-08-25 | Ipsen Ltd | Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample |
| WO2005076785A2 (en) | 2003-12-19 | 2005-08-25 | Wisconsin Alumni Research Foundation | Method and compositions for detecting botulinum neurotoxin |
| ES2374822T3 (es) * | 2004-02-24 | 2012-02-22 | Allergan, Inc. | Ensayo de selección de toxinas botul�?nicas. |
| GB2416849A (en) | 2004-08-04 | 2006-02-08 | Ipsen Ltd | Method for determining the quantity of a pre-synaptic neuromuscular blocking substance in a sample |
| DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| ATE518882T1 (de) | 2005-09-19 | 2011-08-15 | Allergan Inc | Mit clostridientoxin aktivierbare clostridientoxine |
| US8949033B2 (en) | 2006-04-28 | 2015-02-03 | The Chemo-Sero-Therapeutic Research Institute | Method for quantification of neurotoxin |
| US8067192B2 (en) * | 2007-06-05 | 2011-11-29 | City Of Hope | Methods for detection of botulinum neurotoxin |
| EP2235161A1 (en) * | 2007-12-11 | 2010-10-06 | Research Development Foundation | Small molecules for neuronal differentiation of embryonic stem cells |
| EP2254608B1 (en) * | 2008-02-07 | 2016-05-04 | Shahar Cohen | Compartmental extract compositions for tissue engineering |
| PT2271670E (pt) | 2008-03-14 | 2014-11-28 | Allergan Inc | Ensaio imunobaseado da atividade do serotipo a da toxina botulínica |
| US8669048B2 (en) * | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
| EP2191847A1 (en) * | 2008-11-19 | 2010-06-02 | Merz Pharma GmbH & Co.KGaA | Method for preparing compositions comprising a protein, water and glycerol |
| WO2010096746A1 (en) * | 2009-02-20 | 2010-08-26 | Cellular Dynamics International, Inc. | Methods and compositions for the differentiation of stem cells |
| KR101720961B1 (ko) * | 2009-02-27 | 2017-03-29 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | 다능성 세포의 분화 |
| BRPI1008940A2 (pt) | 2009-03-13 | 2020-10-27 | Allergan, Inc. | linhagem de célula clonal estabelecida suscetível à intoxicação por bont/a |
| WO2011031568A2 (en) * | 2009-08-27 | 2011-03-17 | Synaptic Research, Llc | A NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS |
| US20120322670A1 (en) | 2009-08-28 | 2012-12-20 | Cellular Dynamics International, Inc. | Identifying genetic variation in affected tissues |
| WO2011056971A2 (en) | 2009-11-04 | 2011-05-12 | Cellular Dynamics International, Inc. | Episomal reprogramming with chemicals |
| WO2012123370A1 (en) | 2011-03-11 | 2012-09-20 | Merz Pharma Gmbh & Co. Kgaa | Method for the determination of botulinum neurotoxin biological activity |
| DK2694644T3 (en) * | 2011-03-30 | 2018-04-16 | Cellular Dynamics Int Inc | Priming of pluripotent stem cells for neural differentiation |
| EP2798077A2 (en) * | 2011-12-31 | 2014-11-05 | Allergan, Inc. | Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A |
| CA2866595A1 (en) * | 2012-03-07 | 2013-09-12 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for determining neurotoxin activity based on a modified luciferase |
| US8778623B2 (en) * | 2012-09-14 | 2014-07-15 | Wisconsin Alumni Research Foundation | Compositions and methods of using differentiated cells sensitized to botulinum neurotoxin |
| US9102901B2 (en) * | 2012-12-20 | 2015-08-11 | Rohm And Haas Electronic Materials Llc | Methods and compositions for removal of metal hardmasks |
-
2012
- 2012-09-28 ES ES12835606.0T patent/ES2653249T3/es active Active
- 2012-09-28 CA CA2850531A patent/CA2850531C/en active Active
- 2012-09-28 RU RU2014117161A patent/RU2616281C2/ru active
- 2012-09-28 HR HRP20171937TT patent/HRP20171937T1/hr unknown
- 2012-09-28 EP EP12835606.0A patent/EP2761065B1/en active Active
- 2012-09-28 US US14/347,074 patent/US9217172B2/en active Active
- 2012-09-28 MX MX2014003874A patent/MX348188B/es active IP Right Grant
- 2012-09-28 AU AU2012315783A patent/AU2012315783B2/en active Active
- 2012-09-28 JP JP2014533369A patent/JP5877617B2/ja active Active
- 2012-09-28 KR KR1020147011026A patent/KR101640694B1/ko active Active
- 2012-09-28 PL PL12835606T patent/PL2761065T3/pl unknown
- 2012-09-28 BR BR112014007717-7A patent/BR112014007717B1/pt not_active IP Right Cessation
- 2012-09-28 LT LTEP12835606.0T patent/LT2761065T/lt unknown
- 2012-09-28 CN CN201280053513.8A patent/CN103958747B/zh active Active
- 2012-09-28 SG SG11201401007SA patent/SG11201401007SA/en unknown
- 2012-09-28 HU HUE12835606A patent/HUE037509T2/hu unknown
- 2012-09-28 WO PCT/US2012/057825 patent/WO2013049508A1/en not_active Ceased
- 2012-09-28 SI SI201231169T patent/SI2761065T1/en unknown
-
2014
- 2014-03-27 IL IL231768A patent/IL231768B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US9217172B2 (en) | 2015-12-22 |
| RU2014117161A (ru) | 2015-11-10 |
| SG11201401007SA (en) | 2014-04-28 |
| EP2761065A1 (en) | 2014-08-06 |
| PL2761065T3 (pl) | 2018-02-28 |
| BR112014007717A2 (pt) | 2017-04-25 |
| AU2012315783B2 (en) | 2015-08-20 |
| HK1199911A1 (en) | 2015-07-24 |
| EP2761065B1 (en) | 2017-12-06 |
| JP2014528724A (ja) | 2014-10-30 |
| KR101640694B1 (ko) | 2016-07-18 |
| CN103958747A (zh) | 2014-07-30 |
| CN103958747B (zh) | 2017-03-01 |
| AU2012315783A1 (en) | 2014-04-17 |
| CA2850531C (en) | 2016-06-07 |
| IL231768A0 (en) | 2014-05-28 |
| WO2013049508A1 (en) | 2013-04-04 |
| IL231768B (en) | 2019-06-30 |
| EP2761065A4 (en) | 2015-05-06 |
| MX348188B (es) | 2017-06-01 |
| JP5877617B2 (ja) | 2016-03-08 |
| LT2761065T (lt) | 2018-01-10 |
| KR20140086981A (ko) | 2014-07-08 |
| MX2014003874A (es) | 2014-08-18 |
| SI2761065T1 (en) | 2018-02-28 |
| ES2653249T3 (es) | 2018-02-06 |
| HUE037509T2 (hu) | 2018-09-28 |
| BR112014007717B1 (pt) | 2021-07-20 |
| RU2616281C2 (ru) | 2017-04-13 |
| CA2850531A1 (en) | 2013-04-04 |
| US20140234857A1 (en) | 2014-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171937T1 (hr) | Pripravci za i postupci ispitivanja toksigenosti | |
| US12275782B2 (en) | Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells | |
| Whitemarsh et al. | Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro | |
| Del Prado et al. | Culture, method, and the content of self-concepts: Testing trait, individual–self-primacy, and cultural psychology perspectives | |
| JP2022130378A (ja) | 細胞性ｖａｍｐ切断アッセイ | |
| BR112016004320A2 (pt) | biossensor, sistema, kit, métodos de determinação ou de identificação e de quantificação de uma concentração de amônia ou íon amônio, de diagnóstico de uma doença metabólica em um sujeito, de determinação da resposta do paciente a uma terapia, de fabricação de um biossensor, de um sistema ou de qualquer tira de teste e de detecção da presença, ausência, ou quantidade de aminoácidos em uma amostra, e, tira de teste | |
| BR112013020454A8 (pt) | Método para medir a atividade de células assassinas naturais nk, proteína de fusão, composição para ativar células nk, kit para medir a atividade de célula nk | |
| MX2007014815A (es) | Metodos de inmunoanalisis mejorados. | |
| PE20141450A1 (es) | Ensayo de lisiloxidasa-homologo 2 y metodos de uso del mismo | |
| MX2017011195A (es) | Metodos para mejorar la captacion especifica de neurotoxinas botulinicas en las celulas. | |
| US20140134643A1 (en) | Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities | |
| MY198250A (en) | Immunochromatographic Device for Extracting and Measuring Sugar Chain Antigen | |
| Grenda et al. | Methods and difficulties in detection of Clostridium botulinum and its toxins | |
| BR112017002247A2 (pt) | métodos, composições e kit para análise da atividade da glicose-6-fosfato desidrogenase em amostras de sangue | |
| Stahl et al. | Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: implications for therapeutic discovery | |
| Sesardic | Bioassays for evaluation of medical products derived from bacterial toxins | |
| Ambrin et al. | Critical analysis in the advancement of cell-based assays for botulinum neurotoxin | |
| WO2011113813A3 (en) | Assay for analytes based on aggregation | |
| RU2016131408A (ru) | Ганглиозиды для стандартизации и повышения чувствительности клеток к нейротоксинам ботулизма в тест-системах in vitro | |
| RU2014110231A (ru) | Мембранный белок микровезикул и его применение | |
| EA202190892A1 (ru) | Клеточные анализы клостридиальных нейротоксинов | |
| Sesardic et al. | Alternatives to the LD50 assay for botulinum toxin potency testing: Strategies and progress towards refinement, reduction and replacement | |
| Meyer et al. | Bayesian statistic: an approach fitted to clinic | |
| Adnan et al. | Botulinum toxin from foodborne hazard to aesthetic and biomedical tool: mechanisms, applications, detection strategies, and future perspectives | |
| Strobel et al. | VOC analysis for rapid, early detection of bacteria, mold, and mycoplasma in cell and tissue cultures |